This mechanism of non‐genomic loss of function, which we have recently observed also in advanced SM,25 let us suppose that the frequency of SETD2 loss of function in solid and hematologic malignancies might be greater than sequencing and copy number data have so far suggested. Here, SETD2 is linked to systemic mastocytosis.